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We searched for protein markers present in blood serum of multiple sclerosis (MS), rheumatoid arthritis
(RA) and systemic lupus erythematosus (SLE) patients in comparison to healthy human individuals. We
used precipitation/extraction methods and MALDI TOF/TOF mass spectrometry, and identiﬁed a protein
with Mr 46 kDa as a fragment of human unconventional myosin IC isoform b (Myo1C). Western
blotting with speciﬁc anti-human Myo1C antibodies conﬁrmed the identity. Screening of blood serum
samples from different autoimmune patients for the presence of Myo1c revealed its high level in MS and
RA patients, relatively low level in SLE patients, and undetected in healthy donors. These data are sug-
gesting that the level of p46 Myo1C in blood serum is a potential marker for testing of autoimmune
diseases.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Blood serum has been extensively explored as a source of
markers, as it may contain not only blood proteins per se, but also
proteins originating from all tissues of the body [1,2]. It is esti-
mated that up to 10,000 different proteins (and/or its fragments)
may be present in the blood serum, and most of them are in very
low concentrations [3]. Selection of a protein preparation, and
especially enrichment procedures, may aid in successful search for
markers [2,3].
Autoimmune diseases are characterized by auto destructive
processes. Initiation of these processes may differ for different
autoimmune diseases, but they may also include similarities re-
lated to execution mechanisms of cells and tissues degradation.
Therefore, it is possible that different autoimmune diseases may
share even presentation of markers. Multiple sclerosis (MS) is anB.V. This is an open access article u
toid arthritis; SLE, systemicinﬂammatory disease in which the myelin sheaths around axons of
brain and spinal cord are damaged, thus, leading to demyelination
and scarring [4]. This results in a wide range of symptoms. Me-
chanisms of MS have autoimmune character, due to cellular and
humoral immune reactions towards brain tissue self-antigens,
mainly the myelin basic protein (MBP) [5]. The key feature of the
MS patients is the formation of inﬂammatory sites in brain tissue,
which may lead to presence of tissue proteins leaking into the
blood [4,5]. RA and SLA also characterized by inﬂammation and
tissue demerged which can elevate of amount of cellular proteins
in blood serum [6,7]. For puriﬁcation and concentration of proteins
for MALDI TOF/TOF a 2,2,2-trichloroacetic acid (TCA)-induced
protein precipitation is frequently used [8,9], although in our
hands TCA-extracted proteins remain out of the study.
We attempted to identify the proteins in TCA-extracted fraction
of blood serum of MS, RA and SLA patients versus normal human
donors and to estimate their potential diagnostic value.
Here, we report identiﬁcation in human blood serum of un-
conventional myosin Ic (Myo1C) that is ubiquitously expressed in
vertebrates. We propose that this protein could serve as a potential
marker for MS, RA and SLE autoimmune disorders.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A typical SDS-electrophoresis in 12% PAG of TCA-extracted proteins isolated
from blood serum of multiple sclerosis patients. M, molecular masses protein
standards. Lanes 1–7, the samples of TCA-extracted proteins. Arrows point at the
polypeptides which were subjected to MALDI-TOF mass spectrometry.
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2.1. Human blood serum samples
Serum was obtained from the peripheral blood of 28 MS pa-
tients (diagnosed according to the McDonald diagnostic criteria for
MS), 12 SLE patients (diagnosed according to ACR criteria for SLE),
12 RA patients (diagnosed according to ACR/EULAR Rheumatoid
Arthritis Classiﬁcation Criteria) and of 12 healthy volunteers. The
samples were collected under the approval of Bio-Ethics Review
Board of the Danylo Halytsky Lviv National Medical University in
accordance with the regulations of the Ministry of Health of Uk-
raine. A documented consent was obtained from all patients in-
cluded in the study, and the form of the informed consent was
approved by the Bio-Ethics Review Board of the Danylo Halytsky
Lviv National Medical University.
2.2. Preparation of TCA-soluble proteins
According to our protocol, 1 ml of blood serum was diluted in
2-fold with phosphate buffer saline (PBS), and then 100% TCA was
added to 10% of ﬁnal concentration. After 30-min incubation at
20 °C, the solution was centrifuged for 15 min at 10,000 g. The
supernatant containing TCA-soluble compounds was isolated and
mixed with acetone in 1:6 ratio, followed by incubation at 20 °C
for 18 h. The precipitate was pelleted by centrifugation for 10 min
at 10,000 g. The pellet was diluted in distilled water and protein
concentration was measured at 280 nm using a NanoDrop ND1000
spectrophotometer (NanoDrop Technologies, USA). The solution
was stored at 20 °C until use.
2.3. SDS-electrophoresis and Western-blot analysis
SDS-electrophoresis in 12% PAG [10] of blood serum TCA-ex-
tracted proteins was followed by gel staining with Coomassie
Brilliant Blue G. For Western blot analysis, proteins were trans-
ferred from the gel onto a nitrocellulose membrane. The mem-
branes were blocked (1 h at 20 °C) with 5% non-fat milk in the PBS
buffer containing 0.05% Tween-20. The blots were washed with
PBS-Tween-20, three times for 5 min each, and then probed with
the speciﬁc Abs. To identify 46 kDa polypeptide in a pool of TCA-
extracted proteins of blood serum, polyclonal anti-MYO1C (N-
terminal region) rabbit antibody (AVIVA SYSTEM BIOLOGY, product
number ARP56292) in 1:1,000 dilution was incubated overnight at
4 °С. Corresponding secondary antibodies were used for ECL de-
tection. Generated images were scanned, digitalized and images
were quantiﬁed using ImageJ software.
2.4. MALDI-TOF mass spectrometry
Individual electrophoretic protein bands were excised from the
gel and subjected to the in-gel trypsin digestion as was described
earlier [11]. To identify the proteins, their tryptic digests were
subjected to peptide mass ﬁngerprinting (PMF) followed by post-
source decoy (PSD) fragmentation. MALDI TOF/TOF mass spectro-
metry was performed on an Ultraﬂex instrument (Bruker, Ger-
many). Samples were mixed with alpha-cyano-4-hydroxy-cin-
namic acid, and loaded on a metal target plate. Mass spectrumwas
collected in the positive mode. i.e. for MHþ ions. Internal cali-
bration was performed with tryptic peptides generated upon auto-
digestion of trypsin added to samples (842.51, 1045.56 and
2211.10 Da). Collected mass spectra were used for searches with
Profound tool of NCBInr database. Search criteria were as follow:
no limitations of species and pI, mass selection as for 10–100 kDa,
MHþ , complete alkylation of Cys, partial oxidation of Met, one
missed cleavage by trypsin, and tolerance of 0.5 Da. Selected mainpeaks were subjected to PSD by LIFT technology developed by
Bruker and available for Ultraﬂex instruments. Fragmentation
spectra were collected, and delta masses of observed fragments
were used for calculation of the sequence.
2.5. Statistical analysis
Signiﬁcance of the difference in a typical experiment was as-
sessed by Student's t-test. The level of signiﬁcance was set at 0.05.
Three levels of signiﬁcance were used *po0.05; **po0.01;
***po0.001.3. Results and discussion
3.1. TCA-extracted blood serum proteins and their characterization
For isolation of the TCA-extracted proteins from blood serum, a
procedure including treatment of blood serum by 10% tri-
chloracetic acid, pelleting of the insoluble debris by centrifugation
and following precipitation of the soluble compounds with acet-
one in 1:6 ratio were used. Fig. 1 shows a typical SDS-PAG elec-
trophoretic proﬁle of the acetone precipitated proteins. We ob-
served that the TCA-soluble fractions contained proteins with the
molecular mass of 66 kDa (Fig. 1, lanes 1–7) and 46 kDa (Fig. 1,
lanes 5, 6).
3.2. Identiﬁcation of MyoC1-like protein in a pool of TCA-extracted
blood serum proteins
We focused further on identiﬁcation of detected proteins,
which are shown in Fig. 1. To identify the polypeptides with mo-
lecular mass of 66 kDa and 48 kDa, MALDI TOF/TOF mass spec-
trometry analysis based on peptide mass ﬁngerprinting was used.
Fig. 2. A full scan of matrix-assisted laser desorption/ionization mass spectrometry of the 48 kDa polypeptide. A, Mass spectrum of the protein p46. The whole spectrum is
shown. B, Results of search using mass list of p46 with ProFound search tool. Note that Z-value of 2.43 indicates highly signiﬁcant identiﬁcation. C, Homology search using
results of identiﬁcation of p46 with BLAST tool conﬁrmed homology to myosin. BLAST search results image is shown.
Fig. 3. The distribution within different ranges of the levels of Myo1C in different
human blood serum samples. MS, multiple sclerosis (n¼27); RA, rheumatoid ar-
thritis (n¼11); SLE, systemic lupus erythematosis (n¼12); NHD, normal human
donors (n¼12).
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serum albumin (data not shown), and therefore we did not con-
tinue its study. A result of 46 kDa protein identiﬁcation is shown in
Fig. 2. This protein showed high similarity to a non-conventional
human myosin IC (accession number EAW90619.1).
3.3. Enhanced expression of p46/unconventional Myo1C in blood
serum of MS, RA and SLE patients
To explore whether the identiﬁed fragment of unconventional
Myo1C in blood serum of MS patients was indeed enriched in the
blood serum of patients with other autoimmune disease, we ad-
ditionally checked the TCA-extracted fractions isolated from blood
serum of MS patient (27 species), RA patient (12 species), SLE
patient (12 species) and 12 samples obtained from normal human
donors. Quantiﬁcation of data of electrophoretic analysis allowed
estimating the relative amount of a 46 kDa protein in different
blood serum species (Fig. 3). High level of detected Myo1C was
observed in the blood serum of multiple sclerosis and rheumatoid
arthritis patients, while relatively low concentration of that
Fig. 4. Detection of Myo1C in the TCA-extracted proteins of samples isolated from
blood serum of multiple sclerosis (MS), rheumatoid arthritis (RA), systemic lupus
erythematosis (SLE) and normal human donors (NHD). (A), SDS electrophoresis in
12% PAG stained with Coomassie G. (B), Western–blotting using a rabbit polyclonal
antibodies against N-terminal region of Myo1C (Aviva System Biology, product
number ARP56292). Arrows in A, point to the positions of p66 and p46 proteins.
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low in healthy donors (Fig. 3).
To check whether the identiﬁed in blood serum 46 kDa protein
indeed corresponds to Myo1C, we performed immunoblotting
study. TCA-extracted samples of blood serum of MS, RA, and SLE
patients containing highest amount of 46 kDa protein were sub-
jected to SDS-electrophoresis, followed by western blotting with
anti-human Myo1C antibody speciﬁc to synthetic peptide directed
to N-terminal part of human Myo1C (Fig. 4). It was found that anti-
human Myo 1C antibody interacts with a 46 kDa polypeptide of
TCA-extracted fraction from blood serum of MS, RA, and SLE pa-
tients. This data additionally proved relationship between the
46 kDa polypeptide and the human Myo1c.
The results of proteome analysis of blood serum clinical sam-
ples are of potential diagnostic signiﬁcance and can also lead to
identiﬁcation of drug targets [1–3]. To address a search of novel
molecular markers of the Multiple sclerosis (MS), we have studied
TCA-extracted proteins obtained from blood serum of 28 MS pa-
tients as well as 12 RA patients, 12 SLE patients and 12 healthy
human donors. A procedure including separation of TCA-insoluble
proteins from TCA-soluble proteins was applied. TCA-soluble
proteins were pelleted with acetone and their characterization was
performed by SDS-electrophoresis, mass-spectrometry and Wes-
tern-blot analysis. It was found that TCA-soluble fraction of blood
serum of the MS patients mostly contained blood serum albumin,
and 46 kDa protein whose MS-sequence and Western blotting
demonstrated strong structural similarity with human un-
conventional myosin 1c isoform b-Myo1C (NM 001080950.1).
High concentration of albumin in human blood serum could
serve as the most likely cause of its appearance in the pool of TCA-
extracted proteins In contrast to this, our attempts to ﬁnd any
published data about the presence of Myo1C or its fragments inhuman blood serum were not successful. Thus, we ﬁrstly detected
a new protein, belonging to subclasses of cellular unconventional
Myo1C in blood serum of the autoimmune patients (MS, RA and
SLE), while blood serum of normal human donors was generally
lacking such a protein marker.
It is known that Myo1C (molecular mass 121.7 kDa with basal
isoelectric point 9.5) is a member of the unconventional class I
myosins of vertebrates, which directly links plasma membrane
with the microﬁlament cortical web [12,13]. This myosin is im-
plicated in a panoply of cell functions such as cytoskeleton orga-
nization, cell motility, and nuclear transcription. Myo1C is abun-
dantly expressed in murine B lymphocytes, and it is preferentially
located at plasma membrane, e.g. microvilli. It was shown that the
Myo1C is involved in the cytoskeleton dynamics and membrane
protein anchoring or sorting in B lymphocytes [12]. High cationic
charge of Myo c1 could serve of explanation for its presence in
TCA-extracted pools extraction from Nets in blood serum with
high acidic solution.
Origination of the 46 kDa form of Myo1c protein in human
blood serum remains unknown. Here, we can offer two possible
scenario of its appearance in blood serum. In ﬁrst case, rising level
of a Myo1C fragment in blood serum of patients with autoimmune
disorders is result of apoptosis of different lymphoid cells in
bloodstream during treatment procedure. Hence, the level of
46 kDa fragment could be tightly associated with blood cells de-
gradation. In this scenario one could also expect the presence of
signiﬁcant amounts of Myo1C in the control blood samples which
was not the case.
In second scenario, elevation of the 46 kDa fragment of Myo1C
in blood serum of autoimmune patients could be caused by in-
crease of NETosis. NETosis is a distinct form of active cell death of
neutrophils, which is characterized by a release of decondensed
chromatin and granular contents to the extracellular space [14].
NETs were shown to ensnare and kill microbes [15]. Experimental
evidence suggests that NETs participate in pathogenesis of auto-
immune and inﬂammatory disorders [16]. Exaggerated NETosis or
diminished NET clearance likely increases risk of autoreactivity to
NET components. Nets as are extracellular structures composed of
chromatin, granule, and other proteins including cytoskeleton
proteins [17]. Nets also contain protease 3 which can be engaged
in restricted proteolysis of NETs component [17] including full
form of uncovential Myosine. We suggest that 46 kDa proteins is a
proteolytic fragment of Myo 1C, amount of which in blood serum
could serve as a quantitative marker of NETosis in human
bloodstream.4. Conclusions
For the ﬁrst time, we isolated from human blood serum a
46 kDa protein identiﬁed as N-fragment of unconventional myosin
1C (isoform_b). Elevation of the amount of this protein in human
blood serum can be associated with the autoimmune disorders.Acknowledgments
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